Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485487 | 0.75 | CDK2 (0.43) | CDK2PIK3CGCYP11B1ELANE | |
| SCHEMBL15688675 | 0.75 | L3MBTL1 (0.41) | NUDT1PIK3CGL3MBTL1XDHSLC22A12 | |
| SCHEMBL15688674 | 0.75 | L3MBTL1 (0.38) | PIK3CGL3MBTL1 | |
| SCHEMBL12778121 | 0.75 | L3MBTL1 (0.31) | L3MBTL1XDHSLC22A12 | |
| SCHEMBL23942101 | 0.72 | PIK3CG (0.36) | NUDT1CDK2PIK3CGL3MBTL1XDH | |
| SCHEMBL15349644 | 0.71 | NUDT1 (0.41) | NUDT1L3MBTL1 | |
| SCHEMBL325037 | 0.71 | CDK2 (0.43) | NUDT1CDK2PIK3CGELANE | |
| SCHEMBL25428487 | 0.69 | TDO2 (0.42) | NUDT1XDHSLC22A12 | |
| SCHEMBL12618990 | 0.69 | NUDT1 (0.38) | NUDT1CDK2PIK3CGL3MBTL1XDH | |
| SCHEMBL921526 | 0.69 | CYP1A2 (0.40) | NUDT1CDK2PIK3CGL3MBTL1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152214-B1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| US-9796733-B2 | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170107236-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| EP-3152214-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187470-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107236-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, PDE3A, PDE5A | NUDT1 249/4885CDK2 2435/4885PIK3CG 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.